US2004259110A1PendingUtilityA1

Gene PRV-1 and its use

41
Priority: Oct 23, 1998Filed: Dec 5, 2003Published: Dec 23, 2004
Est. expiryOct 23, 2018(expired)· nominal 20-yr term from priority
Inventors:Heike Pahl
A61P 7/02A61P 7/00A61P 31/04A61P 35/00A61P 7/06A61P 9/12A61P 35/02A61P 43/00A61P 9/00A61P 25/04A61P 29/00A61P 17/04A61P 13/12A61P 19/06A61K 38/00C07K 14/475C07K 14/47
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This document describes a nucleotide sequence which encodes the PRV-1 protein, and essentially comprises the sequence ID No. 1, and also a process for detecting this gene and the polypeptide encoded by this gene.

Claims

exact text as granted — not AI-modified
1 . An isolated polypeptide, comprising one of the following amino acid sequences: 
 amino acids 1-437 of SEQ. ID NO.: 2;    amino acids 1-409 of SEQ. ID NO.: 2;    amino acids 22-437 of SEQ. ID NO.: 2;    amino acids 22-409 of SEQ. ID NO.: 2;    or a fragment thereof containing at least 50 amino acids.    
     
     
         2 . (Cancelled).  
     
     
         3 . (Cancelled).  
     
     
         4 . An isolated polynucleotide, comprising one of the following nucleotide sequences: 
 nucleotides 1-1600 of SEQ. ID NO.: 1;    nucleotides 36-1346 of SEQ. ID NO.: 1;    nucleotides 36-1262 of SEQ. ID NO.: 1;    nucleotides 39-1346 of SEQ. ID NO.: 1;    nucleotides 39-1262 of SEQ. ID NO.: 1;    nucleotides 99-1346 of SEQ. ID NO.: 1; or    nucleotides 99-1262 of SEQ. ID NO.: 1.    
     
     
         5 . (Cancelled).  
     
     
         6 . (Cancelled).  
     
     
         7 . (Cancelled).  
     
     
         8 . (Cancelled).  
     
     
         9 . Antibody against a polypeptide of  claim 1 , or an epitome thereof.  
     
     
         10 . Antibody according to  claim 9 , characterized in that it is a monoclonal antibody.  
     
     
         11 . Process for detecting polycythaemia vera, characterized in that the polypeptide according to  claim 1  is reacted, in an immunoassay, with one or more antibody(ies) being monoclonal.  
     
     
         12 . Process according to  claim 11 , characterized in that the antibody employed is a polyclonal or monoclonal antibody.  
     
     
         13 . Process for detecting polycythaemia vera, characterized in that the PRV-1 polynucleotide is detected using an RT-PCR method or a blotting method.  
     
     
         14 . Drug for treating polycythaemia vera, characterized in that, in addition to customary excipients, it comprises polyclonal or monoclonal antibodies according to  claim 10 .  
     
     
         15 . Drug, comprising a polypeptide according to  claim 1  and at least one pharmaceutically tolerated excipient.  
     
     
         16 . Drug, comprising a polynucleotide according to  claim 4  and at least one pharmaceutically tolerated excipient.  
     
     
         17 . Use of a polypeptide according to  claim 1  as a growth factor.  
     
     
         18 . Use of polypeptide according to  claim 1  for producing a drug for treating pancytopenias and pancytopathies in the bone marrow and in the circulation.  
     
     
         19 . Use of a polynucelotide according to  claim 4  for producing a drug for treating pancytopenias and pancytopathies in the bone marrow and in the circulation.  
     
     
         20 . Use of a polypeptide according to  claim 1  for treating and/or multiplying endogenous cells and/or established cell lines ex vivo or in vitro.  
     
     
         21 . Kit for detecting polycythaemia vera, comprising at least one polynucleotide according to  claim 4 , or a fragment thereof.  
     
     
         22 . Kit for detecting disturbances of the haematopoietic system, comprising at least one polynucleotide according to  claim 4 , or a fragment thereof.  
     
     
         23 . Kit for detecting the PRV-1 protein according to  claim 21 , characterized in that it is an ELISA test kit.  
     
     
         24 . Kit for detecting polycythaemia vera, comprising at least one polypeptide according to  claim 1 .  
     
     
         25 . Kit for detecting polycythaemia vera, comprising at least one antibody according to  claim 9 .  
     
     
         26 . Kit for detecting polycythaemia vera, comprising at least one antibody according to  claim 10 .  
     
     
         27 . Kit for detecting disturbances of the haematopoietic system, comprising at least one polypeptide according to  claim 1 .  
     
     
         28 . Kit for detecting disturbances of the haematopoietic system, comprising at least one antibody according to  claim 9 .  
     
     
         29 . Kit for detecting disturbances of the haematopoietic system, comprising at least one antibody according to  claim 10.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.